Literature DB >> 11603952

Vasoactive intestinal polypeptide as mediator of asthma.

D A Groneberg1, J Springer, A Fischer.   

Abstract

Vasoactive intestinal polypeptide (VIP) is one of the most abundant, biologically active peptides found in the human lung. VIP is a likely neurotransmitter or neuromodulator of the inhibitory non-adrenergic non-cholinergic airway nervous system and influences many aspects of pulmonary biology. In human airways VIP-immunoreactive nerve fibres are present in the tracheobronchial airway smooth muscle layer, the walls of pulmonary and bronchial vessels and around submucosal glands. Next to its prominent bronchodilatory effects, VIP potently relaxes pulmonary vessels. The precise role of VIP in the pathogenesis of asthma is still uncertain. Although a therapy using the strong bronchodilatory effects of VIP would offer potential benefits, the rapid inactivation of the peptide by airway peptidases has prevented effective VIP-based drugs so far and non-peptide VIP-agonists did not reach clinical use. Copyright 2001 Academic Press

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11603952     DOI: 10.1006/pupt.2001.0306

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  19 in total

1.  Translocation of Bax and Bid to mitochondria, endoplasmic reticulum and nuclear envelope: possible control points in apoptosis.

Authors:  Barbara Gajkowska; Urszula Wojewódzka; Joanna Gajda
Journal:  J Mol Histol       Date:  2004-01       Impact factor: 2.611

Review 2.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.

Authors:  S A Tannu; L M Renzetti; N Tare; J D Ventre; D Lavelle; T A Lin; A Morschauser; J Paciorek; D R Bolin; H Michel; L Singer; M Hargaden; Id Knowles; P Gardiner; M Cazzola; L Calzetta; M G Matera; A Hicks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.

Authors:  Paul A J Beckers; Jan F Gielis; Paul E Van Schil; Dirk Adriaensen
Journal:  Ann Transl Med       Date:  2017-03

5.  [Effects of vasoactive intestinal peptide on airway inflammation and Th17/Treg balance in asthmatic mice].

Authors:  Li-Qin Ke; Feng-Mei Wang; Yun-Chun Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-06

6.  Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms.

Authors:  Shuang Zhang; Yun Liu; Shouli Guo; Jianing Zhang; Xiaojie Chu; Chun Jiang; Daling Zhu
Journal:  J Physiol Sci       Date:  2010-08-07       Impact factor: 2.781

7.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

8.  Glucocorticoid receptor expression on acute lung injury induced by endotoxin in rats.

Authors:  Yu-Cai Zhang; Wen-Qiong Zuo; Qun-Fang Rong; Guo-Liang Teng; Yu-Ming Zhang
Journal:  World J Emerg Med       Date:  2010

9.  Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.

Authors:  Renaud Dérand; Alicia Montoni; Laurence Bulteau-Pignoux; Thierry Janet; Bertrand Moreau; Jean-Marc Muller; Frédéric Becq
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

10.  Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.

Authors:  Ag Mathioudakis; V Chatzimavridou-Grigoriadou; E Evangelopoulou; Ga Mathioudakis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.